Literature DB >> 22785018

Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.

Kumi Yamada1, Hisae Niki, Hitoshi Nagai, Masakuni Nishikawa, Haruto Nakagawa.   

Abstract

To clarify the involvement of 5-hydroxytryptamine (5-HT) in promotion of thrombogenesis in diabetes, we examined the inhibitory effect of sarpogrelate, a 5-HT(2A) receptor antagonist, on thrombus formation in diabetic rats. In streptozotocin-induced diabetic rats, polyethylene tube-induced thrombus formation was enhanced compared with that in normal rats. The thrombogenesis was inhibited by sarpogrelate; cilostazol, a PDE3 inhibitor; and aspirin, a COX inhibitor, by 75.8%, 42.3%, and 34.3%, respectively. The inhibition by sarpogrelate was more pronounced in diabetic rats than normal ones. High glucose and 5-HT increased the expression of vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) and combination of both high glucose and 5-HT further potentiated the effect. Sarpogrelate but not aspirin inhibited the increase in VCAM-1 expression induced by high glucose and 5-HT. These findings suggest that 5-HT mediates the enhanced thrombogenesis in diabetes and suggests that a 5-HT(2A) receptor antagonist may have novel therapeutic potential for the treatment of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22785018     DOI: 10.1254/jphs.12009fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

1.  Mechanism of contractile dysfunction induced by serotonin in coronary artery in spontaneously hypertensive rats.

Authors:  Hao Wang; Xiao-Yan Gao; Fang Rao; Hui Yang; Zhao-Yu Wang; Lin Liu; Su-Juan Kuang; Qi Wu; Chun-Yu Deng; Jing-Song Xu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-24       Impact factor: 3.000

2.  Sarpogrelate inhibits the expression of ICAM-1 and monocyte-endothelial adhesion induced by high glucose in human endothelial cells.

Authors:  Ying Su; Nan Mao; Min Li; Xia Dong; Fan-Zhen Lin; Ying Xu; Yan-Bo Li
Journal:  Mol Cell Biochem       Date:  2012-10-31       Impact factor: 3.396

Review 3.  Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease.

Authors:  Yu Yang; Hui Huang; Zheng Xu; Jun-Kai Duan
Journal:  J Diabetes Res       Date:  2017-08-08       Impact factor: 4.011

Review 4.  The serotonergic system dysfunction in diabetes mellitus.

Authors:  Yan Cai; Xiaolong Li; Hongli Zhou; Jiyin Zhou
Journal:  Front Cell Neurosci       Date:  2022-07-14       Impact factor: 6.147

5.  Untargeted serum metabolomics and tryptophan metabolism profiling in type 2 diabetic patients with diabetic glomerulopathy.

Authors:  Fanliang Zhang; Ruixue Guo; Wen Cui; Li Wang; Jing Xiao; Jin Shang; Zhanzheng Zhao
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

6.  Upregulation of 5-hydroxytryptamine receptor signaling in coronary arteries after organ culture.

Authors:  Chun-Yu Deng; Hui Yang; Su-Juan Kuang; Fang Rao; Yu-Mei Xue; Zhi-Ling Zhou; Xiao-Ying Liu; Zhi-Xin Shan; Xiao-Hong Li; Qiu-Xiong Lin; Shu-Lin Wu; Xi-Yong Yu
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

7.  Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes.

Authors:  José-Ángel García-Pedraza; Pedro Ferreira-Santos; Rubén Aparicio; María-José Montero; Asunción Morán
Journal:  Sci Rep       Date:  2016-09-23       Impact factor: 4.379

8.  AGEs/RAGE blockade downregulates Endothenin-1 (ET-1), mitigating Human Umbilical Vein Endothelial Cells (HUVEC) injury in deep vein thrombosis (DVT).

Authors:  Yunxin Zhang; Jianlong Liu; Wei Jia; Xuan Tian; Peng Jiang; Zhiyuan Cheng; Jinyong Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.